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ABSTRACT 
 
The Effects of Estrogen on Theiler’s Virus Infection of Endothelial Cells. (April 2009) 
 
Steven M. Maher 
Department of Biomedical Science 
Texas A&M University 
 
Research Advisor: Dr. Jane Welsh 
Department of Veterinary Integrative Biosciences 
 
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central 
nervous system. The pathogenesis of this disease is not fully understood, but it is thought 
to be triggered by viral infection during early adulthood and is followed by autoimmune-
mediated demyelination. Sex hormones are involved in the pathogenesis of MS since 
during pregnancy, women with MS undergo remission of the disease. Our laboratory 
uses Theiler’s virus-induced demyelination (TVID) as the animal model for studying 
MS. Theiler’s virus is a naturally occurring pathogen of mice, which causes an 
autoimmune-mediated demyelination of the central nervous system resulting in 
inflammatory lesions with similarities to human MS. In the current study we examined 
the effects of estrogen on Theiler’s virus infection of cells that form the blood-brain 
barrier (BBB): cerebral vascular endothelial (CVE) cells in vitro. The hypotheses to be 
tested were that (1) estrogen would have a protective effect on the CVE cells and that (2) 
estrogen treatment would alter the expression of microRNAs. Cloned CVE cells from 
BALB/c and C57Bl/6 mice were used in these experiments, which remain diploid and 
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retain their differentiation markers for at least 20 passages in culture. In order to 
determine the effect of estrogen on modulating microRNAs within CVE, RNA was 
isolated from the cells and incorporated into miRNA chip analysis.  We found miRNAs 
that are highly expressed in CVE: Let-7a, mmu miR-21, mmu miR-25, mmu miR-341, 
mmu miR-423, mmu miR-690. Cells were pre-treated with either 17β-estradiol, or ER-α 
agosnist propyl pyrazole triol (PPT) or ER-β agonist diarylpropionitrile (DPN). CVE 
cells were infected with TMEV at MOI of 10.0 for 24, 48, and 72h.  Subsequently, the 
supernatants were used to measure cytotoxicity by LDH release assay. The results 
demonstrate that estrogen has a protective effect on CVE cells infected with TMEV and 
may therefore aid in the maintenance of the BBB integrity during viral infection.  These 
results suggest that estrogen may have beneficial effects in a virus model of MS and may 
also be relevant for MS therapy. 
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NOMENCLATURE 
 
MS Multiple Sclerosis 
CNS Central Nervous System 
EAE Experimental Autoimmune Encephalomyelitis 
TVID Theiler’s Virus-Induced Demyelination 
CVE Cerebrovascular Endothelial 
DPN Diarylpropionitrile 
PPT Propy pyrazole triol 
ER Estrogen Receptor 
MOI  Multiplicity of Infection 
IMDM Iscove’s Modified Dulbecco’s Medium 
FBS Fetal Bovine Serum 
BSA Bovine Serum Albumin 
LDH Lactate Dehydrogenase 
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CHAPTER I 
INTRODUCTION 
 
Multiple Sclerosis (MS)                                                                                                
Multiple Sclerosis is the most common, chronic inflammatory demyelinating disease of 
the central nervous system (CNS), occurring at a prevalence of approximately 350,000 
in the United States and 2.5 million worldwide(Compston and Coles, 2002).  A recent 
study estimated the total average cost to be $47,215 per patient per year which included 
medical and non-medical costs(Kobelt et al., 2006).  The pathogenesis of MS is not 
completely understood, but the disease produces a hallmark appearance as plaque 
formation in the white matter of the CNS.  This plaque is thought to be a result from 
immune-mediated demyelination of axons(Noseworthy et al., 2000).  MS is an 
extremely debilitating disease and has symptoms that reflect its pathological plaque 
formation which may include, but not limited to, gait ataxia, limb weakness, pain, 
depression, clumsiness and optic neuritis(Noseworthy et al., 2000).  In most cases 
patients will need the use of a walking aid within 15 years of the initial onset of the 
disease(Weinshenker et al., 1989).  The initial onset of MS usually occurs between the 
ages of 15 and 40, and typically follows the relapsing remitting course of pathogenesis, 
in which the patient has an acute relapse for approximately 24 hours and then remission 
_______________ 
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which may last months or even years(Orhun and Brian, 2005).  Most patients will 
eventually develop the secondary progressive form of the disease in which the clinical 
signs and symptoms progressively worsen.  This transition is thought to be mediated by 
accumulative neurodegeneration and cerebral atrophy(Orhun and Brian, 2005).  
Although MS is rarely a cause of direct death, a recent study has shown that increased 
suicide rates are associated with this disease, resulting in premature death(Goldman 
Consensus Group, 2005). 
 
Viral etiology of MS 
Genetic background and environmental factors appear to attribute to the etiology of MS.  
Although the etiology of MS is not completely understood, epidemiological studies have 
implicated an infective agent as a probable initiating factor(Acheson, 1977).  Another 
epidemiological study reported increased risk of developing MS was associated with 
measles, mumps, and Epstein-Barr viruses occurring at older ages in childhood(Hernan 
et al., 2001).  Viruses also have known to cause demyelination in animals: mouse 
hepatitis virus, measles virus in rats, herpes simplex in rabbits and Theiler’s virus in 
mice(Dal Canto, 1982).  Theiler’s virus infection in mice represents an excellent model 
for study of the pathogenesis of MS.  
 
Theiler’s virus as a model for MS 
There are two recognized animal models for studying MS: experimental autoimmune 
encephalomyelitis (EAE) and virus-induced demyelination.  EAE is useful to study the 
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autoimmune aspects of MS by initiating auto reactivity to myelin components of the 
CNS.  Theiler’s virus-induced demyelination (TVID), is one of the most commonly 
researched viral models and provides a unique model for the study of MS.  Theiler’s 
virus is a cardiovirus belonging to the family Picornaviridae, which is a naturally 
occurring pathogen of mice(Lipton, 1975; Theiler, 1937).  This virus causes autoimmune 
demyelination in the CNS of mice resulting in the inflammatory lesions which are 
similar to patients with MS(Lipton, 1975; Lucchinetti et al., 2000).  The pathogenesis 
and mechanism of demyelination by TVID is not fully understood, but is partly mediated 
by: direct viral lysis of oligodendrocytes, autoimmunity, cytotoxic T cell reactivity, and 
bystander demyelination mediated by virus-specific DTH T cells(Borrow et al., 1998; 
Gerety et al., 1994; Rodriquez and Sriram, 1988; Roos and Wollmann, 1984).   
 
Estrogen hormones  
During the development of select neuronal groups, estrogen has shown to promote 
growth and differentiation as well as stimulate the expression of growth factors, 
cytoskeletal proteins and enzymes. There are two forms of estrogen receptors (ER) that 
have been identified, the classical estrogen receptor (Green et al., 1986), now called ER-
α, and the newly cloned ER-β(Mosselman et al., 1996). Activated ER interacts with a 
number of other target proteins, which initiate chromatin remodeling and recruit RNA 
polymerases. Estrogen has been shown to reduce neurotoxicity, improve cerebral blood 
flow and reduce infarct volume in a variety of experimental models(Rusa et al., 1999). 
Although the hormonal mechanism is not understood, it is likely that estrogen acts on 
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both neuronal and vascular components. A recent study showed that estrogen can affect 
the endothelium, by increasing responsiveness to endothelial-vasodilators seen after 
ischemia(Watanabe et al., 2001). There are three commonly used estrogens; 17β-
estradiol, the ER-α ligand agonist propyl pyrazole triol (PPT) and the ER-β ligand 
agonist diarylpropionitrile (DPN). 17β-estradiol can bind to both estrogen receptors, 
therefore potentially producing a more profound effect.     
 
Gender and sex hormones in MS and EAE 
Multiple sclerosis is similar to other autoimmune diseases, in that there is a marked 
gender biased where women are twice as likely to develop MS as men(Confavreux et al., 
1980).  Although females seem to be more susceptible to the disease, their condition is 
less severe than males with MS who tend to deteriorate faster(Kremenchutzky et al., 
1999).  Although females have a higher risk of MS, female hormones appear to help 
improve symptoms of established MS.  Therapy with estrogen has shown to alter T-cell 
activation and cytokine expression, as well as have strong neuroprotective effects by 
promoting axon and myelin survival(Tomassini and Pozzilli, 2006).  In pregnant women, 
the relapse rate was reduced in the third trimester when estrogen levels are the highest, 
but worsened and then returned to normal after giving birth(Confavreux et al., 1998).  
Interestingly MS symptoms worsen during pre-menstruation and menopause when 
estrogen levels are decreased, but these symptoms are reduced by hormonal 
replacement(Smith and Studd, 1992).  These studies suggest a neuroprotective effect of 
estrogen on MS.  The effects of estrogen have also been investigated in the autoimmune 
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model EAE, which demonstrated that ER-α ligand treatment abrogated the disease at 
onset and ER-β ligand treatment promoted recovery during the chronic stage. Also, ER-α 
ligand treatment was anti-inflammatory in the systemic immune system as well as the 
CNS, whereas ER-β ligand treatment was not (Tiwari-Woodruff et al., 2007).  17β-
estradiol has shown to reduce EAE in mice by inhibiting cell migration to the CNS, 
increasing T-cell regulatory effects, and through neuroprotective measures that promote 
myelin survival (Halina Offner, 2006).  
 
Impact of sex hormones in Theiler’s virus 
The effects of sex hormones on viral models of MS are not completely understood but 
do show some positive results.  One study showed that male mice infected with TVID 
had higher viral loads in the early stage of the disease and worse demyelinating effects in 
the late stage compared to females(Alley et al., 2003).   The result of this particular 
experiment concludes that estrogen could have a potential anti-viral effect.  Another 
study showed that in-vitro estrogen treatment had inhibitory effects on viral replication 
in macrophages which correlates with earlier findings.  Also, estrogen treatment 
inhibited VCAM-1 expression induced by tumor necrosis factor-alpha in cerebrovascular 
endothelial cells via inhibition of nuclear factor-kappa B (NFkB)(Fuller et al., 2005). 
Overall, estrogen treatment appears to show anti-inflammatory effects, decreased viral 
replication, and reduced infiltration of activated immune cells into the CNS.  Although 
studies of estrogen have shown to have neuroprotective roles in the early stage of 
infection, the effects of estrogen have not been studied on the late demyelinating stage in 
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this model.  The results of this research will aid in our understanding of the pathogenesis 
of multiple sclerosis and may lead to the development of therapeutic treatments. 
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CHAPTER II 
METHODOLOGY 
 
Cerebrovascular endothelial cell isolation and purification  
For our studies it was imperative to produce CVE cells completely free from 
contamination of microglia, astrocytes and fibroblasts.  The CVE cells were taken from 
2-4 week old BALB/c and C57BL/6 mice and were isolated from the cerebrovascular 
microvessels by means of homogenization and filtration (Sapatino et al., 1993).  These 
cells were then characterized with respect to Factor VIII-related antigen, angiotensin 
converting enzyme and uptake of acetylated low density lipoprotein.  They retain their 
differentiation markers and remain diploid at least 20 passages.  The cells were then 
frozen down using standard techniques and placed into a liquid nitrogen container for 
future use. 
 
Virus  
The BeAn 8683 strain of Theiler’s virus (kindly provided by Dr. H. L. 
Lipton, Department of Microbiology-Immunology, University of Illinois at 
Chicago, IL) was initially propagated in lung tumor (L2) cells (Welsh et 
al., 1995).  The virus was tittered using plaque assay method and found to have a 
concentration of 8.3x106 pfu.  
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Experimental design for infection of BALB/c CVE cells 
A preliminary experiment was conducted using BALB/c CVE cells. 
 
Cell count and calculation of MOI for BALB/c CVE cells 
Cloned CVE cells were first grown in culture, a T25 flask, with Iscove’s modified 
Dulbecco’s medium (IMDM) containing 10% charcoal stripped fetal bovine serum 
(FBS), which has all estrogens removed, until a monolayer was established. Trypsin was 
used to release all cells adhering to the flask and the cells were re-suspended in 5ml of 
media. The cell suspension was mixed thoroughly and 20µl was removed and placed into 
a 1ml tube along with 20µL of trypan blue. This mixture was then placed into a 
hemacytometer. The hemacytometer was viewed under microscope and the average 
number of cells was determined by counting the cells in five different boxes. This 
number was then used to determine the amount of virus needed in order to make a MOI 
of 1.0 and 0.1. 
 
 
Infection of BALB/c with BeAn 
The CVE cells were either treated with 2nM 17β-estradiol dissolved in water four hours 
prior to infection or in the case of the control, media alone. The stock solution of 17β-
estradiol was dissolved in water to obtain the correct concentration. After treatment with 
17β-estradiol, the media was removed and the CVE cells were infected with Theiler’s 
virus at a MOI of 0.1 and 1.0 in BSA (Sigma, IL), with or without 17β-estradiol.  The 
virus was left on the CVE cells for 45 minutes and then removed.  The cultures were 
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then prepared with IMDM containing 2% charcoal stripped FBS, with or without 17β-
estradiol and left for 24 hours at which point the cells were observed microscopically. 
The supernatant was collected and spun down at 250 x g for 10 min, to remove all of the 
cells. The supernatant was used for further experiments and the cells were collected for 
miRNA analysis.  This experiment was conducted for preliminary data. Table 1 shows 
the set-up.  
 
 
Table 1 
Set-up for infection with or without 17β-estradiol 
 
Culture   Amount of  Amount of  
Number  Virus (MOI)  17β-estradiol 
 
1  0.0   0.0 
2  0.0   2nM 
3  0.1   0.0 
4  0.1   2nM 
5  1.0   0.0 
6  1.0   2nM 
Note: Each culture was grown in a T25 flask 
 
Detection for cell death of BALB/c cells by means of LDH assay  
Lactate Dehydrogenase (LDH) is a stable enzymatic enzyme that is present in all cells. 
LDH is rapidly release into the culture supernatant when the cell membrane is damaged, 
which makes it an ideal marker for determining cell death. This assay provides a simple 
yet precise colorimetric method to measure LDH activity.  Supernatant was collected in 
separate labeled 10ml tubes to determine the cell-mediated cytotoxicity in each culture.  
The supernatant was spun down at 250 x g for 10 min to remove all dead cells and any 
other contaminants.  A 96-well flat-bottom plate was then prepared by adding 100µl of 
IMDM with 2% FBS to each well except for the first column.  After centrifuging the 
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tubes, 200ul of supernatant was removed from each tube and transferred to the 
corresponding well in the first column.  Each well was diluted using the doubling 
dilutions method and 100µl of reaction mixture was added to each well then incubated 
for 30 min protected from light.  The plates were then measured with a multi-well plate 
reader at an absorbance of 520nm with a reference wavelength no greater than 600nm.  
This experiment was conducted as a preliminary run. Table 2 shows the set-up. 
 
 
Table 2 
Set-up for the 96-well flat-bottom plate 
Dilution 1 ½ ¼ 1/8 
Low Control 
 
 
High Control 
 
MOI 1.0 
 
MOI 0.1 
 
Estrogen + MOI 
1.0 
 
Estrogen + MOI 
0.1 
200µl of cell 
free  
supernatant 
 
 
 
 
 
 
 
 
 
 
 
100µl media + 
100µl from 
column 1 
 
 
 
 
 
 
 
 
 
 
 
100µl media + 
100µl from 
column 2 
 
 
 
 
 
 
 
 
 
 
 
100µl media + 
100µl from 
column 3 
 
 
 
 
 
 
 
 
 
 
 
Note: Remove 100µl from column 5 when finished, final amount should be 100µl in each well 
Note: Add 100µl of reaction mixture to each well when finished with set-up 
 
Calculating the percent cytotoxicity 
In order to determine the effects of estrogen on the CVE cells, a calculation was derived 
to obtain the percent cytotoxicity. The calculation is given in Fig. 1. 
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Test Well LDH release – Min LDH release 
Cytotoxicity (%) = 
Max LDH release - Min LDH release 
 x 100 
 
Fig. 1. Equation used to calculate percent cytotoxicity for BALB/c CVE cells. 
 
Obtaining the maximum and minimum LDH release   
In order to compare the percent cytotoxicity between the test wells, a maximum and 
minimum control must be obtained. To determine the maximum amount of LDH 
released by cell death, cells were treated with Triton X-100 at a final concentration of 
1% in solution. This detergent will cause 100% cell death at this concentration without 
interfering with LDH activity. To obtain the minimum LDH release, cells were cultured 
without virus and estrogen, which corresponds to spontaneous cell death. 
 
MicroRNA analysis 
RNA was extracted from CVE cells in collaboration with Dr. Steelman and Dr. Farida 
Sohrabji. The sample was then divided into two aliquots and labeled with Cy-3 and Cy-5 
fluorescent dyes and hybridizedcompetitively to a miRNA microarray.  
 
Experimental design for infection of C57Bl/6 CVE cells 
This experiment was conducted after the conclusion of the preliminary experiment. 
 
Cell count and calculation of MOI for C57Bl/6 CVE cells 
Cloned C57Bl/6 CVE cells were first grown in three 24-well plates with IMDM 
containing 10% charcoal stripped FBS, until a monolayer was established. The cells 
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were then trypsinized to release all cells from adhering to the well and re-suspended in 
2ml of media. The cell suspension was mixed thoroughly and 20µl was removed and 
placed into a 1ml tube along with 20µL of Trypan blue. This mixture was then placed 
into a hemacytometer. The hemacytometer was viewed under microscope and the 
average number of cells was determined by counting the cells in five different boxes. 
This number was then used to determine the amount of virus needed in order to make a 
MOI of 10.0.  
 
Infection of C57Bl/6 with BeAn 
The CVE cells were either treated with 2nM 17β-estradiol dissolved in water, or 10nM 
DPN dissolved in ethanol, or 2nM PPT dissolved in ethanol four hours prior to infection 
or in the case of the control, media with or without ethanol. The stock solutions of the 
estrogens were diluted in their corresponding solution to obtain correct concentrations. 
After treatment with 17β-estradiol, DPN, or PPT the media was removed and the CVE 
cells were infected with Theiler’s virus at a MOI of 10.0 in BSA (Sigma, IL), with or 
without 17β-estradiol, DPN or PPT.  The virus was left on the CVE cells for 45 minutes 
and then removed.  The cultures were then prepared with IMDM containing 2% charcoal 
stripped FBS, with or without 17β-estradiol, DPN or PPT and left for 24, 48 or 72 hours, 
at which point the cells were observed microscopically.  The supernatant was collected 
in 1.5ml tubes at each time point and spun down at 250 x g for 10 min, to remove all 
cells. The collected supernatant was then placed in a -80°C freezer until needed for 
future experiments. Table 3 shows the set-up. 
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Table 3 
Set-up of the 24-well plate for infection with or without estrogen 
 1 2 3 4 5 6 
A – 24hr 
 
 
B – 48 hr 
 
 
C – 72 hr 
 
 
D 
Control 
 
  
Control 
 
  
Control 
 
 
 Blank 
High 
Control 
 
High 
Control 
 
High 
Control 
 
Blank 
Control + 
estrogen 
 
Control + 
estrogen 
 
Control + 
estrogen 
 
Blank 
Virus MOI 
10.0 
 
Virus MOI 
10.0 
 
Virus MOI 
10.0 
 
Blank 
MOI 10.0 + 
estrogen 
 
MOI 10.0 + 
estrogen 
 
MOI 10.0 + 
estrogen 
 
Blank 
Blank 
 
 
Blank 
 
 
Blank 
 
 
Cell count  
Note: Each plate has either 17β-estradiol, DPN or PPT as the estrogen 
 
Detection for cell death of C57Bl/6 CVE cells by means of LDH assay  
Supernatant was collected in separate labeled 1.5ml tubes to determine the percent 
cytotoxicity in each culture.  The supernatant was spun down at 250 x g for 10 min to 
remove all dead cells.  A 96-well flat-bottom plate was then prepared by adding 100µl of 
IMDM with 2% charcoal stripped FBS to each well except for the 1st, 5th and 9th 
columns.  After centrifuging the tubes, 200ul of supernatant was removed from each 
tube and transferred to the corresponding well.  Each well was diluted using the doubling 
dilutions method and 100µl of reaction mixture was added to each well then incubated 
for 30 min protected from light.  The plates were then measured with a multi-well plate 
reader (Fluostar Optima), at an absorbance of 520nm with a reference wavelength no 
greater than 600nm.  This experiment was conducted in triplicates. Table 4 shows the 
set-up.  
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Table 4 
Set-up for the 96-well flat-bottom plate at 24, 48 and 72 hrs 
Dilution 1 ½ ¼ 1/8 
 
Media 
 
 
Low Control 
 
 
High Control 
 
 
Control + 17β-estradiol 
 
 
MOI 10.0 + 17β-estradiol 
 
 
MOI 10.0 
200µl of 
cell free  
supernatant 
 
100µl media 
+ 100µl from 
column 1 
 
100µl media 
+ 100µl from 
column 2 
 
100µl media 
+ 100µl from 
column 3 
 
Note: Remove 100µl from column 4 when finished, final amount should be 100µl in each well 
Note: Each 96-well flat-bottom plate has this set-up repeated three times  
Note: Replace 17β-estradiol with DPN or PPT supernatant for other 96-well plates 
 
Calculating the percent cytotoxicity 
In order to determine the effects of estrogen on the CVE cells, a calculation was derived 
to obtain the percent cytotoxicity. Fig. 2 shows the equation. 
  
Average LDH release - Min LDH release 
Cytotoxicity (%) = 
Max LDH release - Min LDH release 
X 100 
 
Fig. 2. Equation used to calculate percent cytotoxicity for C57Bl/6 CVE cells 
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Obtaining the maximum and minimum LDH release  
In order to compare the percent cytotoxicity between the test wells, a maximum must be 
obtained. To determine the maximum amount of LDH released by cell death, cells were 
treated with Triton X-100 at a final concentration of 1% in solution. This detergent will 
cause 100% cell death at this concentration without interfering with LDH activity To 
obtain the minimum LDH release, cells were cultured without virus and estrogen, which 
corresponds to spontaneous cell death. 
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CHAPTER III 
RESULTS 
 
Experimental results for infection of BALB/c CVE cells 
The preliminary study for this experiment showed signs that estrogen had 
neuroprotective effects on CVE cells infected with TVID. 
 
Cell count and calculation of MOI 
Cells were counted in order to determine the amount of virus needed to induce an 
infection of a certain magnitude. Fig. 3 shows the results of the calculation. 
 
  Cell Count:   37 
          48  
          55 
          38 
          47 
         225/ 5 = 45 
 
        45 x 104 = 4.5 x 105/ ml · 10 = 4.5 x 106 total cells 
 
  Dilution Factor 
 
          8.3 x 106       
          4.5 x 106   = 1.844 
 
        MOI 1.0 = 1.0ml virus in 0.844ml media 
    
        MOI 0.1 = 0.1ml virus in 0.844ml media          
 
Fig 3. Cell count and calculation of MOI of 1.0 and 0.1 
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LDH cytotoxicity assay of BALB/c CVE cells 
Estrogen treated BALB/c cells that were infected with TVID, had decreased LDH 
activity, as shown in Fig. 4. The calculation given in the methods was used to determine 
the percent cytotoxicity of each culture. Cells that were infected at a MOI of 1.0 and 
treated with 17β-estradiol had an average percent cytotoxicity of 31.15% (p≤ .05) less 
than non-treated cells. Also, cells infected at a MOI of 0.1 and treated with 17β-estradiol 
had an average percent cytotoxicity of 19.09% (p ≤ .05) less than non-treated cells. 
 
0
10
20
30
40
50
60
MOI 1.0  MOI 0.1
Multiplicity of Infection
C
y
to
to
x
ic
ity
 (
%
) 
  
   
   Virus + Estradiol
Virus
 
Fig. 4. The difference in cytotoxicity between infected cells. Cells were treated with 17β-estradiol and not 
treated with 17β-estradiol. At MOI 1.0 there was 31.15% (p≤ .05) difference between cells treated with 
17β-estradiol and not treated with it. At MOI 0.1 there was 19.09% (p ≤ .05) difference between cells 
treated with 17β-estradiol and not treated. 
 
 
 
To calculate the average percent of overall cytotoxicity, the values of percent 
cytotoxicity for each dilution were combined. Fig. 5 shows the results of the individual 
dilution average percent cytotoxicity.  
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Fig. 5. Percent cytotoxicity for individual dilutions. (A) The average percent cytotoxicity was determined 
at a MOI of 1.0 at each dilution, and it showed that the levels maintained their differences. (B) The 
average percent cytotoxicity was determined at a MOI of 0.1 at each dilution, and it showed that the levels 
maintained their differences. 
 
 
MicroRNA analysis 
The resulting “same on same” hybridization pattern revealed that highly expressed 
microRNAs in BALB/c endothelial cells are: Let-7a, mmu miR-21, mmu miR-25, mmu   
miR-341, mmu miR-423, mmu miR-690. These results indicate that these miRNA's are 
candidate markers for CVE cells, or at least CVE cells express them ubiquitously.  
 
Experimental results for infection of C57Bl/6 CVE cells 
After obtaining data from the preliminary experiment it was decided to complete a full 
project using C57Bl/6 CVE cells. 
 
Cell count and calculation of MOI 
Cells were counted in order to determine the amount of virus needed, to induce an 
infection of a certain magnitude. Fig. 6 shows the results of the calculation. 
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Cell Count:   3 
          5  
          2 
          4 
          3 
          17/ 5 = 3.4 
 
        3.4 x 104 / ml x 4 = 1.36 x 105 total cells per well 
 
  Dilution Factor 
 
          8.3 x 106        
         0.136 x 106   = 61.029 
 
                                  MOI 10.0 = 1.0ml virus in 6.0ml media 
 
Fig. 6. Cell count and calculation of MOI of 10.0. 
 
 
LDH cytotoxicity assay of C57Bl/6 CVE cells – 24hrs 
After conclusion of the experiment the supernatant was used to determine the effects of 
estrogens by means of percent cytotoxicity. The supernatant was collected at 24, 48 and 
72 hour marks.  At 24hrs the cells were still confluent and maintained their monolayer. 
When the supernatant was collected and spun down, very few cells were seen at the 
bottom of the tube. The cell-free supernatant was tested for cell death LDH release.   
The LDH assay had similar results as the preliminary experiment. All of the estrogens 
decreased the percent cytotoxicity, but only 17β-estradiol was by a significant amount. 
17β-estradiol decreased the percent cytotoxicity by 1.79% (p≤ .05). The other two 
estrogens, DPN and PPT also decreased the percent cytotoxicity, which shows a strong 
trend. DPN decreased the average percent cytotoxicity by 1.83% (p≥ .05) and PPT 
decreased the average percent cytotoxicity by 1.57% (p≥ .05). Fig. 7 shows the results.  
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Fig. 7. Difference between estrogen treated and not treated cells at 24hrs. 17β-estradiol decreased the 
percent cytotoxicity by 1.79% (p≤ .05). DPN decreased the average percent cytotoxicity by 1.83% (p≥ .05) 
and PPT decreased the average percent cytotoxicity by 1.57% (p≥ .05). 
 
 
The averages for the above results were determined by combining the averages for each 
dilution. Fig. 8 shows the individual results for each type of estrogen with respect to the 
dilution principle. 
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Fig. 8. Individual averages of percent cytotoxicity for each estrogen at 24hrs. (A) 17β-estradiol averages. 
(B) DPN averages. (C) PPT averages. 
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Fig. 8 Continued.  
 
 
LDH cytotoxicity assay of C57Bl/6 CVE cells – 48hrs 
The cell cultures were examined at 48hrs and the supernatant was removed.  The cells 
treated with estrogen were approximately 90% confluent, compared to the cells not 
treated with estrogen which were approximately 75% confluent. The supernatant had 
few cells, but the supernatant that was treated with estrogen had less. The supernatant 
was measured using the LDH assay, and the results showed that estrogen was still 
decreasing the LDH activity. The results of the assay demonstrated that PPT had the 
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greatest decline in percent cytotoxicity on infected cells, 5.89% (p ≤ .05). PPT was the 
only estrogen that displayed statistically significant data, but 17β-estradiol and DPN also 
decreased percent cytotoxicity of infected cells. 17β-estradiol decreased the amount by 
2.83% (p ≥ .05) and DPN decreased the percent by 2.36% (p ≥ .05). Although these two 
estrogens were not statistically significant they did display a strong trend in decreasing 
the percent cytotoxicity. Fig. 9 displays the results. 
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Fig. 9. Difference between estrogen treated and not treated cells at 48hrs. 17β-estradiol decreased the 
percent cytotoxicity by 2.83% (p≥ .05). DPN decreased the average percent cytotoxicity by 2.36% (p≥ .05) 
and PPT decreased the average percent cytotoxicity by 5.89% (p≤ .05). 
 
The averages for the above results were determined by combining the averages for each 
dilution. Fig. 10 shows the individual results for each type of estrogen with respect to the 
dilution principle. 
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Fig. 10. Individual averages of percent cytotoxicity for each estrogen at 24hrs. (A) 17β-estradiol averages. 
(B) DPN averages. (C) PPT averages. 
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LDH cytotoxicity assay of C57Bl/6 CVE cells – 72hrs 
The last extraction of supernantant was made at the 72hr mark and the cells were 
observed closely. The cultures that were infected and not treated with estrogen were 
approximately 60% confluent and there were a lot of dead cells floating. The cultures 
that were infected and treated with estrogen were approximately 75% confluent but there 
were less dead cells floating compared to the cultures not treated with estrogen. The 
supernatant was measured using the LDH assay, and the results showed that estrogen 
was still decreasing LDH activity. The results of the assay demonstrated that both 17β-
estradiol and PPT decreased the percent cytotoxicity compared to the cultures that were 
not treated with estrogen. 17β-estradiol decreased the percent cytotoxicity by 8.12% (p≤ 
.05) and PPT decreased the percent cytotoxicity by 2.46% (p≤ .05). DPN on the other 
hand had not effect on the percent cytotoxicity compared to the culture not treated with 
estrogen. Fig. 11 displays the average results for the effects of estrogen on TVID 
infected CVE cells at the 72hr mark. 
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Fig 11. Difference between estrogen treated and not treated cells at 72hrs. 17β-estradiol decreased the 
percent cytotoxicity by 8.12% (p≤ .05) and PPT decreased the percent cytotoxicity by 2.46% (p≤ .05). 
DPN on the other hand had not effect on the percent cytotoxicity compared to the culture not treated with 
estrogen. 
 
 
The averages for the above results were determined by combining the averages for each 
dilution. Fig. 12 shows the individual results for each type of estrogen with respect to the 
dilution principle. 
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Fig. 12. Individual averages of percent cytotoxicity for each estrogen at 72hrs. (A) 17β-estradiol averages. 
(B) DPN averages. (C) PPT averages.  
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
The present studies indicate that both BALB/c and C57Bl/6 CVE cells are susceptible to 
TVID infection in vitro. The studies also demonstrate that both strains of cells are 
directly affected by estrogen but the pattern and extent of neuroprotection are not the 
same. Estrogen reduced the LDH activity in both BALB/c and C57Bl/6 CVE cells, but 
the treatment decreased the cytotoxicity of TVID on BALB/c cells by a much greater 
margin. Also, 17β-estradiol and PPT showed to have a significant reduction in LDH 
activity on C57Bl/6 CVE cells, while DPN did not have a significant decrease.  
 
Discussion 
So what does all this mean? There are a couple of possibilities that can be drawn from 
this experiment. First of all, the data suggests that BALB/c CVE cells are more 
susceptible to estrogen response compared to C57Bl/6 CVE cells. This could mean that 
BALB/c CVE cells have more estrogen receptors than C57Bl/6 CVE cells. This 
conclusion can be drawn because of the greater significant difference in LDH activity 
between BALB/c CVE cells and C57Bl/6 CVE cells treated with estrogen. Further 
studies should be completed to compare the difference in CVE cells between strains to 
determine the difference in cytotoxicity. Another conclusion that can be drawn from this 
experiment is that 17β-estradiol and PPT have a more profound effect on CVE cells than 
compared to DPN. This could possibly be due to the fact that CVE cells have more ER-α 
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ligand binding sites than ER-β ligand binding sites. While estrogens have proven to be 
neuroprotective, some are consider useful during onset of disease while others show 
their action during the chronic stage of the disease. The experiment that was conducted 
shows the results of the onset of the disease because cells were only infected for 72hrs. 
This shows that the ER-α agonist PPT has a greater effect on CVE cells during the onset 
of TVID than DPN. These results coincide with a study completed on EAE, another 
model for Theiler’s virus, which shows the ER-α agonist PPT abrogated the disease at 
onset and throughout the course of the disease, while DPN only showed neuroprotective 
effects during the chronic stage (Tiwari-Woodruff et al., 2007). This experiment allowed 
us to obtain crucial preliminary data for further studies with estrogen on Theiler’s virus. 
The results in this experiment have set-up a basic understanding of the effects of 
estrogen on TVID. Future experiments should be conducted on the effects of estrogen at 
pregnancy concentrations, the effect of estrogens on CNS helper cells and the effects of 
estrogens on Theiler’s virus in vivo. With further studies, a possible treatment could be 
obtained for patients with MS.    
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